PTGX: financial statements from SEC — TradeAlmanac

PTGX

Protagonist Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	56m	5m	6m	28m	5m	4m
Research and development	47m	40m	37m	36m	36m	34m
Selling, general and administrative	13m	11m	11m	12m	10m	9m
Operating expenses	60m	51m	48m	48m	46m	43m
Operating income	−4m	−46m	−42m	−19m	−41m	−39m
Pre-tax income	2m	−39m	−35m	−12m	−34m	−31m
Income tax	−2m	0	172,000	0	−420,000	−676,000
Net income	4m	−39m	−35m	−12m	−33m	−31m
Earnings per share	0.06	−0.62	−0.55	−0.19	−0.54	−0.50
Earnings per share, diluted	0.05	−0.62	−0.55	−0.19	−0.54	−0.50
Weighted average shares	65m	64m	64m	63m	62m	61m
Weighted average shares, diluted	70m	64m	64m	63m	62m	61m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	194m	128m	114m	169m	140m	97m	131m	356m
Short-term investments	354m	439m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−49m	125m
Depreciation and amortisation	407,000	239,000
Share-based compensation	15m	14m
Capital expenditure	215,000	545,000
Investing cash flow	91m	−94m
Financing cash flow	23m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)